Skip to main content
September 20

September 20, 2017
Barcelona, Spain

ESSD

European Society for Swallowing Disorders

20.09. - 23.09.2017

NEXT EVENT

September 20

September 20, 2017
Nice, France

EUGMS

European Union Geriatric Medicine Society

20.09 - 22.09.2017

NEXT EVENT

September 09

September 09, 2017
The Hague, The Netherlands

ESPEN

European Society for Clinical Nutrition and Metabolism

09.09. - 12.09.2017

NEXT EVENT

September 08

September 08, 2017
Madrid, Spain

ESMO - Europe

European Society for Medical Oncology

08.09. - 12.09.2017

NEXT EVENT

June 17

June 17, 2017
Copenhagen, Denmark

ISBT - Europe

International Society of Blood Transfusion

17.06. - 21.06.2017

NEXT EVENT

June 03

June 03, 2017
Geneva, Switzerland

Euroanaesthesia

03.06. - 05.06.2017

NEXT EVENT

June 03

June 03, 2017
Madrid, Spain

ERA-EDTA

54th Congress of European Diaysis and Transplant Association

03.06. - 07.06.2017

NEXT EVENT

  • No conditions by Spanish antitrust authority
  • Closing of transaction expected by January 31, 2017

Fresenius Helios today received antitrust approval to acquire Quirónsalud, Spain’s largest private hospital operator. The relevant Spanish antitrust authority has approved the transaction without imposing conditions. The acquisition can therefore be closed by January 31, 2017. Quirónsalud will be consolidated as of February 1, 2017.

Quirónsalud’s network is comprised of 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (“ORP”) centers located in all economically important areas in Spain. The company has about 35,000 employees and offers the full spectrum of inpatient and outpatient care. With the acquisition, Fresenius Helios strengthens its position as Europe’s largest private hospital operator.

Given the expected meaningful accretion to Group sales and earnings, Fresenius will publish new mid-term targets as part of its full-year 2016 reporting.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

May 17

May 17, 2017
Copenhagen, Denmark

ISFA

11th International Society for Apheresis Congress

17.05. - 20.05.2017

NEXT EVENT

May 10

May 10, 2017
Prague, Czech Republic

ESPGHAN

European Society for Paediatric Gastroenterology, Hepatology and Nutrition

10.05. - 13.05.2017

NEXT EVENT

Subscribe to